EMA Panel Backs Carfilzomib Label Update in Myeloma

January 30, 2018 – The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a label variation for carfilzomib in patients with relapsed/refractory multiple myeloma. If approved by the EMA, the adjusted label will include updated overall survival (OS) data from the phase III ENDEAVOR trial. In results from the study published in The Lancet Oncology, carfilzomib reduced the … (leggi tutto)